Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well rituximab, venetoclax, and bortezomib work in treating
 patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond
 to treatment (refractory). Immunotherapy with monoclonal antibodies, such as rituximab, may
 help the body's immune system attack the cancer, and may interfere with the ability of tumor
 cells to grow and spread. Venetoclax and bortezomib may stop the growth of tumor cells by
 blocking some of the proteins needed for cell growth. Giving rituximab, venetoclax, and
 bortezomib may slow or stop the growth of cancer cells in patients with diffuse large B-cell
 lymphoma.
PRIMARY OBJECTIVE:

 I. To determine the overall response rate (ORR) of rituximab, venetoclax, and bortezomib in
 relapsed/refractory diffuse large B-cell lymphoma.

 SECONDARY OBJECTIVES:

 I. To describe the safety profile of rituximab, venetoclax, and bortezomib in diffuse large
 B-cell lymphoma (DLBCL).

 II. To describe the progression free survival of subjects enrolled to the study.

 III. To describe the median overall survival of subjects enrolled to the study. IV. To
 describe the complete remission (CR) rate, the partial remission (PR) rate and the duration
 of response (DoR) of rituximab, venetoclax, and bortezomib in relapsed/refractory DLBCL.

 EXPLORATORY OBJECTIVE:

 I. To describe the association of BCL2 expression status, measured by immunohistochemistry
 (IHC), with ORR, CR and PR rates.

 OUTLINE:

 Patients receive rituximab intravenously (IV) on day -1 of cycle 1, then on day 1 of cycles
 2-6. Patients also receive venetoclax orally (PO) once daily (QD) on days 1-14 and bortezomib
 IV or subcutaneously (SC) on day -1 of cycle 1, then on days 1, 8, and 15 of subsequent
 cycles. Treatment repeats every 28 days for up to 6 cycles for rituximab and up to 26 cycles
 for venetoclax and bortezomib in the absence of disease progression or unacceptable toxicity.

 After completion of study treatment, patients are followed up at 30 days.
Inclusion Criteria:

 -  Relapsed/refractory DLBCL defined as any of the following:

 -  Confirmed DLBCL/Burkitt lymphoma (BL)/B-cell lymphoma, unclassifiable (BCLU) by
 World Health Organization (WHO) 2016 classification

 -  Double hit lymphoma (DHL) phenotype as confirmed by FISH (fluorescent in-situ
 hybridization) or IHC (immunohistochemistry)

 -  Relapsed or progression of disease after at least one prior line of standard
 rituximab-cyclophosphamide-hydroxydaunorubicin-oncovin-prednisone (R-CHOP),
 rituximab-etoposide-prednisone-oncovin-cyclophosphamide-hydroxydaunorubicin (R-EPOCH)
 or other R-CHOP-like therapy

 -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

 -  No prior treatment with a proteasome inhibitor or prior BCL2 inhibitor

 -  No cytotoxic chemotherapy within 2 weeks prior to study treatment

 -  Patients who are not candidates for salvage stem cell transplant or patients who are
 not candidates for CAR-T (chimeric antigen receptor T-cell) therapy, patients who have
 progressed or relapsed after a salvage transplant or CAR-T therapy are eligible

 -  Patients must give informed consent

 -  Prior radiation therapy allowed to < 25% of the bone marrow and patients must have
 recovered from the toxic effects of the treatment prior to study enrollment (except
 for alopecia). Patients treated with standard postoperative adjuvant radiation therapy
 for other cancers are allowed. Prior radiotherapy must be completed 14 days before
 study entry. Lesions that have been radiated in the advanced setting cannot be
 included as sites of measurable disease unless clear tumor progression has been
 documented in these lesions since the end of radiation therapy

 -  Patients with lower blood counts due to marrow involvement by DHL will be eligible for
 the study

 -  Absolute neutrophil count (ANC) >= 1,000/uL

 -  Platelets >= 50,000/uL

 -  Total bilirubin within normal institutional limits

 -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
 [SGOT]/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <
 3 X institutional upper limit of normal (ULN)

 -  Creatinine < 1.5 the upper limit of normal

 Exclusion Criteria:

 -  Patients who have had prior proteasome inhibitor therapy or prior therapy with
 venetoclax

 -  Patients with known brain metastases will be excluded from this clinical trial because
 of their poor prognosis and because they often develop progressive neurologic
 dysfunction that would confound the evaluation of neurologic and other adverse events

 -  Serious concomitant systemic disorders (including active infections) that would
 compromise the safety of the patient or compromise the patient's ability to complete
 the study, at the discretion of the investigator

 -  Patients with history of hepatitis B with negative viral load are eligible (including
 latent carriers and patient with history of active disease who required treatment)

 -  History of allergic reactions attributed to compounds of similar chemical or biologic
 composition to venetoclax and bortezomib or other agents used in the study

 -  Subjects with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome
 (AIDS) which is not well controlled on antiviral therapy

 -  Patients who have received autologous hematopoietic stem cell transplantation within
 12 months

 -  Subject has received the following within 7 days prior to the first dose of study
 drug: Steroid therapy for anti-neoplastic intent, strong and moderate CYP3A inhibitors
 and/or strong and moderate CYP3A inducers

 -  The effects of combination venetoclax and bortezomib may cause fetal harm. For this
 reason, women of child-bearing potential and men must agree to use adequate
 contraception (hormonal or barrier method of birth control; abstinence) prior to study
 entry, for the duration of study participation and for 12 weeks after. Should a woman
 become pregnant or suspect she is pregnant while participating in this study, she
 should inform her treating physician immediately